🌍 Climate change impacts kidney health.
This #WorldKidneyDay, protect your kidneys and the planet.
Learn more: www.worldkidneyday.org/2026-campaign/
Take the kidney quiz: kidneyquiz.theisn.org
Find the clinical evidence on treatments @DRUGDOCS®.
#OurKidneysOurPlanet #KidneyHealthForAll #DrugDocs
📊 Top 3 drugs searched on DRUGDOCS® in February:
1️⃣ TNKase® – Stroke and heart attack thrombolytic
2️⃣ Zolymbus™ – Glaucoma ophthalmic gel
3️⃣ Aristada® – Injectable schizophrenia therapy
Explore the evidence: drugdocs.com
#DrugDocs #StrokeCare #Glaucoma #MentalHealth #Pharma
Counting down the Top 3 Drug Searches on @drugdocs.bsky.social in 2025.
#3: YERVOY® (ipilimumab). In 2025, FDA approved nivolumab + ipilimumab for MSI-H/dMMR metastatic CRC and unresectable/metastatic HCC.
💊 Find the clinical evidence for #Yervoy at: drugdocs.com/drug/Yervoy
#Oncology #DRUGDOCS
As this year comes to an end, we are counting down the top 3 drugs most searched on DRUGDOCS® in 2025! Stay tuned for the reveal in January!
#EvidenceBasedMedicine #DRUGDOCS
Top 3 drugs searched on DRUGDOCS® in November:
1. Tezspire®: Severe asthma biologic
2. Zolymbus®: Glaucoma eye treatment
3. Sovaldi®: Chronic hepatitis C antiviral
Explore the clinical evidence behind these drugs and more at drugdocs.com
#Pharma #DrugData #Asthma #Glaucoma #HepatitisC #DRUGDOCS
@who.int issues its first global GLP-1 guideline for obesity, warning that by 2030 <10% of eligible people may have access.
💊 Find the clinical evidence for GLP-1 therapies at @drugdocs: drugdocs.com/search/GLP-1
🔗 Read more here: www.who.int/news/item/01...
#GLP1 #PublicHealth #DRUGDOCS
FDA approves HYRNUO® (sevabertinib) for adults with HER2 activating mutations in non-small cell lung cancer post-systemic therapy.
🧪 ORR: 71% in HER2-targeted naïve patients
🕒 Median DOR: 9.2 months
📌 See the clinical evidence at DRUGDOCS: drugdocs.com/drug/Hyrnuo
#LungCancer #FDAApproval #DRUGDOCS
Top 3 drugs searched on DRUGDOCS® in October:
1. Hercessi® – HER2+ cancer biosimilar
2. Yervoy® – CTLA-4 inhibitor for cancer
3. Tyenne® – RA & GCA biosimilar
Explore the clinical evidence behind these drugs and more at drugdocs.com
#DrugDocs #Oncology #Biosimilars #PharmaData
Bayer’s Lynkuet (elinzanetant) has received FDA approval to treat moderate to severe vasomotor symptoms including hot flashes and night sweats, during menopause.
🔍 Explore the clinical evidence for Lynkuet at DRUGDOCS® drugdocs.com/drug/Lynkuet
#FDA #PharmaUpdate #MenopauseTreatment #DrugDocs
